EAM
LEGN icon

Exane Asset Management’s Legend Biotech LEGN Stock Holding History

Exane Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-67,782
Closed -$2.28M – 33
2024
Q4 		$2.28M Buy
+67,782
New +$2.81M 1.3% 15

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Exane Asset Management's LEGN Position: Q1 2025 in Review

Exane Asset Management sold out of Legend Biotech (LEGN) in Q1 2025, closing a stake of 67,782 shares — an estimated $2.28M sold.

Exane Asset Management first reported a position in LEGN in Q4 2024 and held it in 1 quarter. The position peaked at $2.28M in Q4 2024. 208 funds tracked by Wall St. Rank hold LEGN as of Q1 2025.

  • Exane Asset Management reported no remaining Legend Biotech position as of Q1 2025 after selling out during the quarter.
  • Exane Asset Management sold 67,782 Legend Biotech shares in Q1 2025, an estimated $2.28M.
  • Exane Asset Management first reported a position in Legend Biotech in Q4 2024 and held it in 1 quarter.
  • Exane Asset Management's Legend Biotech position peaked at $2.28M in Q4 2024.
  • 208 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2025.

Based on Exane Asset Management's 13F filing for Q1 2025, filed 30 Apr 2025.